Document is current
Any future updates will be listed below
-
Authors
Ottilie, Sabine
Luth, Madeline R.
Hellemann, Erich https://orcid.org/0000-0002-5565-8614
Goldgof, Gregory M.
Vigil, Eddy
Kumar, Prianka
Cheung, Andrea L.
Song, Miranda https://orcid.org/0000-0003-4448-277X
Godinez-Macias, Karla P.
Carolino, Krypton
Yang, Jennifer
Lopez, Gisel
Abraham, Matthew
Tarsio, Maureen
LeBlanc, Emmanuelle https://orcid.org/0000-0003-4278-0984
Whitesell, Luke https://orcid.org/0000-0001-6445-5766
Schenken, Jake
Gunawan, Felicia
Patel, Reysha
Smith, Joshua
Love, Melissa S.
Williams, Roy M.
McNamara, Case W.
Gerwick, William H. https://orcid.org/0000-0003-1403-4458
Ideker, Trey
Suzuki, Yo
Wirth, Dyann F.
Lukens, Amanda K.
Kane, Patricia M.
Cowen, Leah E. https://orcid.org/0000-0001-5797-0110
Durrant, Jacob D.
Winzeler, Elizabeth A. https://orcid.org/0000-0002-4049-2113
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1054480)
Bill and Melinda Gates Foundation (OPP1141300)
Bill and Melinda Gates Foundation (OPP1171497)
Bill and Melinda Gates Foundation (OPP1107194)
Bill and Melinda Gates Foundation
Bill and Melinda Gates Foundation
U.S. Department of Health & Human Services | National Institutes of Health (GM085764)
U.S. Department of Health & Human Services | National Institutes of Health (R01AI120958-01A1)
U.S. Department of Health & Human Services | National Institutes of Health (GM127364)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM008666)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Bill and Melinda Gates Foundation
- License Information
-
More Information
Article History
Received: 4 June 2021
Accepted: 21 January 2022
First Online: 11 February 2022
Competing interests
: The authors declare the following competing interests: L.E.C. and L.W. are co-founders and shareholders in Bright Angel Therapeutics, a platform company for development of novel antifungal therapeutics. L.E.C. is a consultant for Boragen, a small-molecule development company focused on leveraging the unique chemical properties of boron chemistry for crop protection and animal health. The remaining authors declare no competing interests.
